Alan Palestine
Concepts (670)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Uveitis | 68 | 2023 | 116 | 8.190 |
Why?
| Panuveitis | 4 | 2023 | 7 | 3.510 |
Why?
| Uveitis, Intermediate | 4 | 2023 | 7 | 2.580 |
Why?
| Fluocinolone Acetonide | 3 | 2023 | 16 | 2.480 |
Why?
| Cataract | 6 | 2023 | 194 | 2.460 |
Why?
| Visual Acuity | 26 | 2023 | 275 | 2.250 |
Why?
| Eye Infections, Bacterial | 5 | 2020 | 25 | 2.020 |
Why?
| Retinopathy of Prematurity | 8 | 2020 | 111 | 1.990 |
Why?
| Endophthalmitis | 6 | 2020 | 25 | 1.960 |
Why?
| Macular Edema | 5 | 2023 | 37 | 1.900 |
Why?
| Glucocorticoids | 7 | 2023 | 554 | 1.900 |
Why?
| Scleritis | 3 | 2022 | 18 | 1.810 |
Why?
| Corneal Ulcer | 2 | 2022 | 14 | 1.730 |
Why?
| Vitrectomy | 8 | 2020 | 58 | 1.730 |
Why?
| Macular Degeneration | 9 | 2023 | 152 | 1.620 |
Why?
| Arthritis, Juvenile | 2 | 2022 | 42 | 1.420 |
Why?
| Fluorescein Angiography | 14 | 2023 | 103 | 1.390 |
Why?
| Vitreous Body | 15 | 2022 | 104 | 1.380 |
Why?
| Ocular Hypertension | 4 | 2022 | 60 | 1.210 |
Why?
| Postoperative Complications | 7 | 2021 | 2301 | 1.120 |
Why?
| Cyclosporins | 31 | 1991 | 60 | 1.110 |
Why?
| Cataract Extraction | 4 | 2023 | 82 | 1.030 |
Why?
| Glaucoma | 3 | 2023 | 214 | 1.030 |
Why?
| Drug Costs | 2 | 2016 | 100 | 1.000 |
Why?
| Tomography, Optical Coherence | 4 | 2021 | 134 | 1.000 |
Why?
| Retinal Vessels | 6 | 2021 | 53 | 0.980 |
Why?
| Intraocular Pressure | 9 | 2022 | 286 | 0.970 |
Why?
| Cytomegalovirus Retinitis | 4 | 2016 | 13 | 0.950 |
Why?
| Geographic Atrophy | 5 | 2023 | 51 | 0.940 |
Why?
| Uveitis, Posterior | 5 | 2019 | 12 | 0.920 |
Why?
| Diabetic Retinopathy | 2 | 2022 | 156 | 0.910 |
Why?
| Anterior Chamber | 5 | 2021 | 21 | 0.900 |
Why?
| Inflammation | 10 | 2023 | 2598 | 0.900 |
Why?
| Antirheumatic Agents | 2 | 2022 | 254 | 0.900 |
Why?
| Hematopoietic Stem Cell Transplantation | 2 | 2020 | 543 | 0.890 |
Why?
| Keratoconjunctivitis Sicca | 1 | 2022 | 4 | 0.890 |
Why?
| Retinal Detachment | 3 | 2020 | 55 | 0.880 |
Why?
| Eye Diseases | 10 | 2020 | 78 | 0.880 |
Why?
| Retinitis | 15 | 1993 | 17 | 0.870 |
Why?
| Methotrexate | 3 | 2022 | 227 | 0.860 |
Why?
| Behcet Syndrome | 7 | 2021 | 17 | 0.850 |
Why?
| Humans | 168 | 2023 | 122796 | 0.850 |
Why?
| Corneal Transplantation | 4 | 2020 | 10 | 0.820 |
Why?
| Health Care Costs | 2 | 2016 | 414 | 0.820 |
Why?
| Retinal Diseases | 6 | 2020 | 81 | 0.820 |
Why?
| Acquired Immunodeficiency Syndrome | 22 | 1996 | 222 | 0.810 |
Why?
| Retinal Vasculitis | 1 | 2021 | 7 | 0.800 |
Why?
| Azathioprine | 2 | 2022 | 55 | 0.790 |
Why?
| Eye Banks | 1 | 2020 | 7 | 0.780 |
Why?
| Retrospective Studies | 28 | 2022 | 13433 | 0.750 |
Why?
| Granulomatosis with Polyangiitis | 1 | 2020 | 41 | 0.730 |
Why?
| MAP Kinase Kinase 1 | 1 | 2019 | 67 | 0.700 |
Why?
| Homosexuality, Male | 1 | 2020 | 176 | 0.690 |
Why?
| Practice Patterns, Physicians' | 3 | 2016 | 1267 | 0.650 |
Why?
| Surveys and Questionnaires | 8 | 2022 | 4882 | 0.640 |
Why?
| International Classification of Diseases | 1 | 2018 | 128 | 0.620 |
Why?
| Proto-Oncogene Proteins B-raf | 1 | 2019 | 204 | 0.620 |
Why?
| Sarcoidosis | 9 | 2023 | 132 | 0.610 |
Why?
| Labor, Induced | 1 | 2017 | 32 | 0.600 |
Why?
| Fetal Membranes, Premature Rupture | 1 | 2017 | 40 | 0.600 |
Why?
| Labor, Obstetric | 1 | 2017 | 55 | 0.590 |
Why?
| Adrenal Cortex Hormones | 4 | 2023 | 515 | 0.590 |
Why?
| Retinal Drusen | 3 | 2021 | 25 | 0.590 |
Why?
| Rheumatologists | 1 | 2016 | 12 | 0.590 |
Why?
| Ophthalmologists | 1 | 2016 | 11 | 0.580 |
Why?
| Drug Implants | 5 | 2022 | 71 | 0.580 |
Why?
| Cytomegalovirus | 2 | 2016 | 144 | 0.580 |
Why?
| Conjunctivitis | 2 | 2015 | 19 | 0.570 |
Why?
| Polychondritis, Relapsing | 1 | 2015 | 2 | 0.560 |
Why?
| Autoimmune Diseases | 20 | 2009 | 408 | 0.550 |
Why?
| Ear Auricle | 1 | 2015 | 11 | 0.550 |
Why?
| Insurance, Health | 2 | 2016 | 259 | 0.550 |
Why?
| Vision Disorders | 2 | 2016 | 134 | 0.540 |
Why?
| Adult | 71 | 2022 | 32385 | 0.540 |
Why?
| Wet Macular Degeneration | 3 | 2020 | 32 | 0.530 |
Why?
| Surgical Wound Infection | 1 | 2018 | 251 | 0.520 |
Why?
| Needles | 1 | 2015 | 59 | 0.520 |
Why?
| Female | 98 | 2023 | 63629 | 0.520 |
Why?
| Biopsy, Needle | 1 | 2015 | 192 | 0.510 |
Why?
| Neonatal Screening | 4 | 2018 | 185 | 0.510 |
Why?
| DNA, Viral | 1 | 2016 | 358 | 0.500 |
Why?
| Diabetes Mellitus | 2 | 2022 | 985 | 0.500 |
Why?
| Arthritis, Rheumatoid | 1 | 2022 | 985 | 0.480 |
Why?
| Male | 80 | 2023 | 59639 | 0.480 |
Why?
| Aged | 38 | 2023 | 20495 | 0.470 |
Why?
| Complement Activation | 3 | 2022 | 349 | 0.470 |
Why?
| Middle Aged | 52 | 2021 | 28563 | 0.470 |
Why?
| Premature Birth | 1 | 2017 | 304 | 0.460 |
Why?
| Databases, Factual | 1 | 2018 | 1287 | 0.450 |
Why?
| Gestational Age | 8 | 2020 | 787 | 0.450 |
Why?
| Vaccination | 1 | 2021 | 1241 | 0.440 |
Why?
| Immunosuppressive Agents | 5 | 2022 | 687 | 0.440 |
Why?
| Ophthalmology | 3 | 2022 | 77 | 0.440 |
Why?
| Follow-Up Studies | 12 | 2021 | 4768 | 0.440 |
Why?
| Cytomegalovirus Infections | 12 | 1999 | 188 | 0.440 |
Why?
| Bacteria | 2 | 2018 | 772 | 0.440 |
Why?
| Melanoma | 1 | 2019 | 709 | 0.430 |
Why?
| Placenta | 1 | 2018 | 648 | 0.420 |
Why?
| Steroids | 2 | 2023 | 156 | 0.420 |
Why?
| Antineoplastic Agents | 3 | 2020 | 1990 | 0.410 |
Why?
| Skin Neoplasms | 2 | 2019 | 841 | 0.410 |
Why?
| Electronic Health Records | 1 | 2018 | 842 | 0.410 |
Why?
| Antiviral Agents | 10 | 2001 | 670 | 0.390 |
Why?
| Anti-Bacterial Agents | 2 | 2018 | 1562 | 0.390 |
Why?
| Macula Lutea | 3 | 2020 | 15 | 0.390 |
Why?
| Ciliary Body | 9 | 2018 | 34 | 0.380 |
Why?
| Colorado | 9 | 2022 | 4325 | 0.370 |
Why?
| Trabeculectomy | 2 | 2022 | 71 | 0.370 |
Why?
| Complement Factor B | 2 | 2022 | 102 | 0.360 |
Why?
| Practice Guidelines as Topic | 1 | 2018 | 1519 | 0.360 |
Why?
| Registries | 4 | 2023 | 2020 | 0.360 |
Why?
| United States | 11 | 2023 | 13272 | 0.340 |
Why?
| Aqueous Humor | 4 | 2022 | 31 | 0.340 |
Why?
| Glaucoma, Open-Angle | 2 | 2022 | 98 | 0.340 |
Why?
| Aged, 80 and over | 12 | 2021 | 6845 | 0.340 |
Why?
| Antigens | 14 | 1990 | 337 | 0.330 |
Why?
| Complement System Proteins | 3 | 2022 | 296 | 0.330 |
Why?
| Eye Proteins | 7 | 1990 | 77 | 0.320 |
Why?
| Conjunctival Diseases | 3 | 2017 | 17 | 0.320 |
Why?
| Cyclosporine | 2 | 2022 | 175 | 0.310 |
Why?
| Retina | 18 | 1993 | 277 | 0.300 |
Why?
| Ganciclovir | 8 | 1999 | 46 | 0.300 |
Why?
| Birth Weight | 4 | 2020 | 473 | 0.300 |
Why?
| Adolescent | 27 | 2022 | 18948 | 0.290 |
Why?
| Uveitis, Anterior | 4 | 2018 | 11 | 0.290 |
Why?
| Corneal Diseases | 5 | 2017 | 36 | 0.290 |
Why?
| Incidence | 6 | 2021 | 2527 | 0.280 |
Why?
| Child | 21 | 2022 | 19561 | 0.280 |
Why?
| Opportunistic Infections | 4 | 1991 | 45 | 0.280 |
Why?
| Adalimumab | 2 | 2022 | 44 | 0.270 |
Why?
| Fundus Oculi | 7 | 2021 | 41 | 0.270 |
Why?
| Bromocriptine | 4 | 1990 | 28 | 0.270 |
Why?
| Chemokine CCL5 | 2 | 2023 | 50 | 0.270 |
Why?
| Biological Factors | 2 | 2022 | 42 | 0.270 |
Why?
| Risk Factors | 10 | 2020 | 9381 | 0.250 |
Why?
| Laser Therapy | 5 | 2021 | 105 | 0.250 |
Why?
| Cross-Sectional Studies | 5 | 2022 | 4734 | 0.250 |
Why?
| Specialization | 2 | 2016 | 134 | 0.250 |
Why?
| Time Factors | 12 | 2021 | 6682 | 0.250 |
Why?
| Retinal Vein Occlusion | 1 | 2004 | 13 | 0.240 |
Why?
| Infant, Premature | 2 | 2019 | 507 | 0.240 |
Why?
| Child, Preschool | 9 | 2022 | 9755 | 0.240 |
Why?
| Mycophenolic Acid | 2 | 2022 | 80 | 0.240 |
Why?
| Fluoresceins | 5 | 1989 | 47 | 0.240 |
Why?
| Cohort Studies | 7 | 2020 | 5294 | 0.230 |
Why?
| Quality of Life | 3 | 2023 | 2457 | 0.230 |
Why?
| Choroid | 11 | 2021 | 47 | 0.230 |
Why?
| Phacoemulsification | 3 | 2019 | 104 | 0.230 |
Why?
| Infant, Very Low Birth Weight | 3 | 2018 | 71 | 0.230 |
Why?
| Young Adult | 6 | 2021 | 11094 | 0.220 |
Why?
| Infant | 8 | 2022 | 8523 | 0.220 |
Why?
| Etanercept | 1 | 2022 | 51 | 0.220 |
Why?
| Algorithms | 4 | 2018 | 1593 | 0.220 |
Why?
| Anti-Inflammatory Agents | 3 | 2022 | 469 | 0.220 |
Why?
| Foscarnet | 4 | 1996 | 19 | 0.220 |
Why?
| Histocompatibility Antigens Class II | 9 | 1994 | 397 | 0.220 |
Why?
| Eye Neoplasms | 3 | 2017 | 13 | 0.210 |
Why?
| Reference Standards | 2 | 2022 | 177 | 0.210 |
Why?
| Albumins | 1 | 2022 | 104 | 0.210 |
Why?
| Tacrolimus | 1 | 2022 | 154 | 0.200 |
Why?
| Posterior Capsulotomy | 1 | 2021 | 8 | 0.200 |
Why?
| Posterior Capsule of the Lens | 1 | 2021 | 11 | 0.200 |
Why?
| Antibodies, Monoclonal | 12 | 2020 | 1306 | 0.200 |
Why?
| Eye Infections, Viral | 2 | 1991 | 7 | 0.200 |
Why?
| Rats, Inbred Lew | 18 | 1994 | 87 | 0.200 |
Why?
| AIDS-Related Opportunistic Infections | 2 | 1999 | 114 | 0.200 |
Why?
| Lasers, Solid-State | 1 | 2021 | 24 | 0.200 |
Why?
| Graft Rejection | 3 | 2021 | 556 | 0.200 |
Why?
| Capsule Opacification | 1 | 2021 | 27 | 0.200 |
Why?
| National Eye Institute (U.S.) | 1 | 2020 | 6 | 0.200 |
Why?
| T-Lymphocytes, Helper-Inducer | 8 | 1994 | 133 | 0.200 |
Why?
| Laser Coagulation | 2 | 2018 | 58 | 0.190 |
Why?
| Retinal Pigment Epithelium | 1 | 2021 | 62 | 0.190 |
Why?
| Sensitivity and Specificity | 4 | 2018 | 1855 | 0.190 |
Why?
| Anemia, Sickle Cell | 1 | 2004 | 226 | 0.190 |
Why?
| Glaucoma, Angle-Closure | 1 | 2020 | 16 | 0.190 |
Why?
| Multiple Sclerosis | 3 | 2023 | 395 | 0.180 |
Why?
| Administration, Topical | 4 | 2016 | 154 | 0.180 |
Why?
| Retinal Neovascularization | 1 | 2019 | 21 | 0.180 |
Why?
| Scleral Buckling | 1 | 2019 | 19 | 0.180 |
Why?
| Diagnostic Techniques, Ophthalmological | 2 | 2018 | 35 | 0.180 |
Why?
| Treatment Outcome | 9 | 2022 | 9692 | 0.180 |
Why?
| Endotoxins | 3 | 1991 | 234 | 0.180 |
Why?
| Infant, Newborn | 7 | 2020 | 5430 | 0.180 |
Why?
| Transplantation, Autologous | 1 | 2020 | 189 | 0.180 |
Why?
| Canada | 1 | 2020 | 355 | 0.180 |
Why?
| Complement Membrane Attack Complex | 1 | 2019 | 34 | 0.170 |
Why?
| Complement C3a | 1 | 2019 | 33 | 0.170 |
Why?
| Pyrimidinones | 1 | 2019 | 88 | 0.170 |
Why?
| Tumor Necrosis Factor-alpha | 3 | 2022 | 1181 | 0.170 |
Why?
| Acyclovir | 5 | 2001 | 104 | 0.170 |
Why?
| Induced Pluripotent Stem Cells | 1 | 2021 | 188 | 0.170 |
Why?
| Choroidal Neovascularization | 1 | 2019 | 45 | 0.170 |
Why?
| Estrogen Replacement Therapy | 1 | 2019 | 118 | 0.170 |
Why?
| Computer Systems | 1 | 2018 | 48 | 0.170 |
Why?
| Organ Transplantation | 1 | 2021 | 165 | 0.170 |
Why?
| Immunity, Maternally-Acquired | 1 | 2018 | 26 | 0.170 |
Why?
| Decision Making | 2 | 2016 | 840 | 0.160 |
Why?
| Viral Load | 2 | 2016 | 423 | 0.160 |
Why?
| Biological Products | 1 | 2021 | 166 | 0.160 |
Why?
| Organophosphonates | 1 | 1998 | 96 | 0.160 |
Why?
| Intravitreal Injections | 1 | 2018 | 47 | 0.160 |
Why?
| Disease-Free Survival | 1 | 2019 | 661 | 0.160 |
Why?
| Farber Lipogranulomatosis | 1 | 2017 | 4 | 0.150 |
Why?
| Metformin | 1 | 2021 | 303 | 0.150 |
Why?
| Risk | 4 | 2018 | 890 | 0.150 |
Why?
| Reoperation | 1 | 2020 | 570 | 0.150 |
Why?
| Abnormalities, Multiple | 1 | 2019 | 183 | 0.150 |
Why?
| Synovitis | 1 | 2017 | 24 | 0.150 |
Why?
| Amnion | 1 | 2017 | 27 | 0.150 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2023 | 1260 | 0.150 |
Why?
| Arrestin | 13 | 1990 | 13 | 0.150 |
Why?
| Stevens-Johnson Syndrome | 1 | 2017 | 34 | 0.150 |
Why?
| Parity | 1 | 2017 | 108 | 0.150 |
Why?
| Ophthalmoscopy | 1 | 2016 | 30 | 0.150 |
Why?
| Cicatrix | 1 | 2017 | 54 | 0.150 |
Why?
| Burnout, Professional | 1 | 2022 | 333 | 0.150 |
Why?
| Medical Informatics | 1 | 2017 | 108 | 0.140 |
Why?
| Infant, Low Birth Weight | 1 | 2017 | 130 | 0.140 |
Why?
| Polymerase Chain Reaction | 2 | 2016 | 1021 | 0.140 |
Why?
| Herpes Zoster | 2 | 2009 | 334 | 0.140 |
Why?
| Terminology as Topic | 1 | 2017 | 217 | 0.140 |
Why?
| Arthritis | 1 | 2017 | 115 | 0.140 |
Why?
| T-Lymphocytes | 12 | 2022 | 1814 | 0.140 |
Why?
| Lymphocytes | 9 | 1991 | 360 | 0.140 |
Why?
| Transplantation, Homologous | 2 | 2016 | 413 | 0.140 |
Why?
| Recovery of Function | 1 | 2019 | 610 | 0.140 |
Why?
| Weight Gain | 2 | 2016 | 511 | 0.130 |
Why?
| Microbiological Techniques | 1 | 2015 | 32 | 0.130 |
Why?
| Antineoplastic Agents, Immunological | 1 | 2017 | 159 | 0.130 |
Why?
| Disease Management | 1 | 2019 | 591 | 0.130 |
Why?
| Endoscopy | 1 | 2018 | 267 | 0.130 |
Why?
| Colony Count, Microbial | 1 | 2015 | 124 | 0.130 |
Why?
| Pregnancy | 2 | 2018 | 5854 | 0.130 |
Why?
| Rheumatology | 1 | 2016 | 88 | 0.130 |
Why?
| Hematologic Neoplasms | 1 | 2016 | 135 | 0.130 |
Why?
| Insulin-Like Growth Factor I | 1 | 2017 | 288 | 0.130 |
Why?
| Phosphonoacetic Acid | 2 | 1991 | 10 | 0.130 |
Why?
| Bronchopulmonary Dysplasia | 1 | 2019 | 337 | 0.120 |
Why?
| Lymphocyte Activation | 8 | 1990 | 1148 | 0.120 |
Why?
| Rats | 24 | 1994 | 5426 | 0.120 |
Why?
| Chorioretinitis | 2 | 1992 | 2 | 0.120 |
Why?
| Toxoplasmosis, Ocular | 2 | 1994 | 2 | 0.120 |
Why?
| Health Care Surveys | 1 | 2016 | 564 | 0.120 |
Why?
| Fetus | 1 | 2018 | 699 | 0.120 |
Why?
| Prospective Studies | 6 | 2020 | 6704 | 0.120 |
Why?
| Reproducibility of Results | 2 | 2018 | 2977 | 0.120 |
Why?
| Clinical Decision-Making | 1 | 2016 | 293 | 0.120 |
Why?
| Physicians | 1 | 2022 | 824 | 0.120 |
Why?
| Protein Kinase Inhibitors | 1 | 2019 | 833 | 0.120 |
Why?
| Lymphoma, B-Cell | 2 | 1993 | 90 | 0.120 |
Why?
| CD4-Positive T-Lymphocytes | 2 | 1998 | 1003 | 0.110 |
Why?
| HIV-1 | 1 | 1998 | 783 | 0.110 |
Why?
| Lymphoma, Large B-Cell, Diffuse | 2 | 1992 | 93 | 0.110 |
Why?
| Research Design | 1 | 2019 | 1002 | 0.110 |
Why?
| Health Surveys | 1 | 2014 | 468 | 0.110 |
Why?
| Iris | 3 | 1991 | 19 | 0.110 |
Why?
| HLA Antigens | 7 | 1991 | 230 | 0.110 |
Why?
| Creatinine | 7 | 1992 | 510 | 0.110 |
Why?
| Patient Selection | 1 | 2016 | 717 | 0.110 |
Why?
| Kidney Diseases | 6 | 1989 | 446 | 0.110 |
Why?
| Pars Planitis | 1 | 1992 | 1 | 0.110 |
Why?
| Risk Assessment | 2 | 2019 | 3213 | 0.110 |
Why?
| Mothers | 1 | 2018 | 728 | 0.100 |
Why?
| Retinal Necrosis Syndrome, Acute | 1 | 1991 | 9 | 0.100 |
Why?
| Biomarkers | 5 | 2023 | 3662 | 0.100 |
Why?
| Patient Care Team | 1 | 2016 | 520 | 0.100 |
Why?
| Injections, Intravenous | 7 | 1999 | 217 | 0.100 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 1402 | 0.100 |
Why?
| Capillary Permeability | 2 | 1991 | 148 | 0.100 |
Why?
| Clinical Competence | 1 | 2018 | 973 | 0.100 |
Why?
| HIV | 4 | 2020 | 219 | 0.100 |
Why?
| Bacterial Infections | 3 | 1989 | 234 | 0.090 |
Why?
| Toxoplasma | 2 | 1994 | 34 | 0.090 |
Why?
| Cytophagaceae | 1 | 1990 | 1 | 0.090 |
Why?
| Capnocytophaga | 1 | 1990 | 2 | 0.090 |
Why?
| Antigens, Surface | 3 | 1989 | 166 | 0.090 |
Why?
| Granuloma | 4 | 2023 | 93 | 0.090 |
Why?
| Antigens, Protozoan | 1 | 1989 | 19 | 0.090 |
Why?
| Urine | 1 | 1989 | 65 | 0.090 |
Why?
| Sebaceous Gland Neoplasms | 1 | 1989 | 3 | 0.090 |
Why?
| Eyelid Neoplasms | 1 | 1989 | 7 | 0.090 |
Why?
| Blood Chemical Analysis | 1 | 1989 | 97 | 0.090 |
Why?
| Odds Ratio | 4 | 2019 | 1043 | 0.080 |
Why?
| Animals | 34 | 2021 | 34133 | 0.080 |
Why?
| Drug Therapy, Combination | 5 | 1998 | 988 | 0.080 |
Why?
| Tonometry, Ocular | 2 | 2019 | 92 | 0.080 |
Why?
| Eye | 7 | 1988 | 108 | 0.080 |
Why?
| Postoperative Period | 2 | 2019 | 317 | 0.080 |
Why?
| Enzyme-Linked Immunosorbent Assay | 8 | 2019 | 839 | 0.080 |
Why?
| Extravasation of Diagnostic and Therapeutic Materials | 1 | 1987 | 17 | 0.080 |
Why?
| Antibody Formation | 3 | 1985 | 285 | 0.080 |
Why?
| Dextrans | 1 | 1987 | 77 | 0.070 |
Why?
| Fanconi Syndrome | 1 | 1986 | 2 | 0.070 |
Why?
| Autoantibodies | 6 | 1992 | 1353 | 0.070 |
Why?
| Escherichia coli | 1 | 1991 | 767 | 0.070 |
Why?
| Prednisolone | 2 | 2020 | 76 | 0.070 |
Why?
| Lymphocyte Transfusion | 1 | 1986 | 19 | 0.070 |
Why?
| Immunoenzyme Techniques | 8 | 1991 | 201 | 0.070 |
Why?
| Cell Movement | 2 | 1988 | 929 | 0.070 |
Why?
| Infliximab | 2 | 2021 | 95 | 0.070 |
Why?
| Interferometry | 1 | 1985 | 7 | 0.070 |
Why?
| Lasers | 2 | 1985 | 123 | 0.070 |
Why?
| Phenotype | 4 | 2022 | 3070 | 0.070 |
Why?
| Lenses, Intraocular | 2 | 2021 | 45 | 0.070 |
Why?
| Panophthalmitis | 1 | 1985 | 2 | 0.070 |
Why?
| Uveomeningoencephalitic Syndrome | 3 | 1990 | 6 | 0.060 |
Why?
| Protein S Deficiency | 1 | 2004 | 6 | 0.060 |
Why?
| Choroiditis | 4 | 1991 | 6 | 0.060 |
Why?
| Myopia | 1 | 1984 | 37 | 0.060 |
Why?
| Biopsy | 5 | 1993 | 1090 | 0.060 |
Why?
| Microscopy, Electron | 8 | 1988 | 418 | 0.060 |
Why?
| Tears | 4 | 1987 | 14 | 0.060 |
Why?
| Phagocyte Bactericidal Dysfunction | 1 | 1983 | 12 | 0.060 |
Why?
| Tretinoin | 1 | 1984 | 119 | 0.060 |
Why?
| Retinal Artery | 2 | 1987 | 15 | 0.060 |
Why?
| Ophthalmia, Sympathetic | 3 | 1990 | 3 | 0.060 |
Why?
| Keratoplasty, Penetrating | 2 | 1994 | 5 | 0.060 |
Why?
| Immunologic Memory | 1 | 1985 | 321 | 0.060 |
Why?
| Complement Factor I | 1 | 2022 | 12 | 0.050 |
Why?
| Interleukin-4 | 1 | 2023 | 230 | 0.050 |
Why?
| Case-Control Studies | 2 | 2020 | 3296 | 0.050 |
Why?
| Adenocarcinoma | 1 | 1989 | 837 | 0.050 |
Why?
| Immunohistochemistry | 6 | 1993 | 1727 | 0.050 |
Why?
| Deltaretrovirus | 3 | 1986 | 12 | 0.050 |
Why?
| Aneurysm | 1 | 1982 | 33 | 0.050 |
Why?
| Cavernous Sinus | 1 | 1981 | 16 | 0.050 |
Why?
| 2-Aminopurine | 1 | 2001 | 10 | 0.050 |
Why?
| Herpes Zoster Ophthalmicus | 1 | 2001 | 5 | 0.050 |
Why?
| Arteriovenous Fistula | 1 | 1981 | 31 | 0.050 |
Why?
| Infusions, Intravenous | 2 | 2020 | 396 | 0.050 |
Why?
| Fibrinogen | 1 | 2022 | 162 | 0.050 |
Why?
| Transplantation Tolerance | 1 | 2021 | 32 | 0.050 |
Why?
| Abatacept | 1 | 2021 | 43 | 0.050 |
Why?
| Pigment Epithelium of Eye | 4 | 1990 | 34 | 0.050 |
Why?
| Tertiary Healthcare | 1 | 2020 | 29 | 0.050 |
Why?
| Sickness Impact Profile | 1 | 2020 | 53 | 0.050 |
Why?
| Cyclopentolate | 1 | 2020 | 3 | 0.050 |
Why?
| Microscopy, Acoustic | 1 | 2020 | 8 | 0.050 |
Why?
| Gonioscopy | 1 | 2020 | 7 | 0.050 |
Why?
| Administration, Ophthalmic | 1 | 2020 | 14 | 0.050 |
Why?
| Disease Models, Animal | 3 | 1991 | 3799 | 0.050 |
Why?
| Muscarinic Antagonists | 1 | 2020 | 29 | 0.050 |
Why?
| Amyloidosis | 1 | 2020 | 41 | 0.050 |
Why?
| Kidney | 3 | 1989 | 1355 | 0.050 |
Why?
| Carotid Arteries | 1 | 1981 | 189 | 0.050 |
Why?
| Epithelium | 6 | 1991 | 309 | 0.050 |
Why?
| Immunologic Factors | 1 | 2022 | 228 | 0.050 |
Why?
| Protective Factors | 1 | 2019 | 96 | 0.040 |
Why?
| Immunization, Passive | 3 | 1988 | 82 | 0.040 |
Why?
| C-Reactive Protein | 1 | 2021 | 363 | 0.040 |
Why?
| Drug Combinations | 1 | 2020 | 292 | 0.040 |
Why?
| Anticoagulants | 1 | 2004 | 589 | 0.040 |
Why?
| Cornea | 4 | 1989 | 120 | 0.040 |
Why?
| Sarcoma, Kaposi | 4 | 1999 | 73 | 0.040 |
Why?
| Cytosine | 1 | 1998 | 46 | 0.040 |
Why?
| Hypertension | 5 | 1991 | 1245 | 0.040 |
Why?
| Trabecular Meshwork | 1 | 2019 | 77 | 0.040 |
Why?
| Prolactin | 2 | 1988 | 97 | 0.040 |
Why?
| CD4 Lymphocyte Count | 1 | 1998 | 274 | 0.040 |
Why?
| Conjunctiva | 3 | 1989 | 51 | 0.040 |
Why?
| Retinol-Binding Proteins | 2 | 1988 | 13 | 0.040 |
Why?
| Organophosphorus Compounds | 1 | 1998 | 78 | 0.040 |
Why?
| Academic Medical Centers | 1 | 2020 | 427 | 0.040 |
Why?
| Logistic Models | 2 | 2019 | 1995 | 0.040 |
Why?
| Fluorometholone | 1 | 2017 | 4 | 0.040 |
Why?
| Drug Evaluation | 2 | 1988 | 82 | 0.040 |
Why?
| Group Processes | 1 | 2017 | 57 | 0.040 |
Why?
| North America | 1 | 2018 | 271 | 0.040 |
Why?
| Nod2 Signaling Adaptor Protein | 1 | 2017 | 30 | 0.040 |
Why?
| Chemotaxis, Leukocyte | 2 | 1987 | 135 | 0.040 |
Why?
| Administration, Oral | 3 | 1999 | 786 | 0.040 |
Why?
| Sex Characteristics | 1 | 2022 | 690 | 0.040 |
Why?
| Observer Variation | 1 | 2017 | 314 | 0.040 |
Why?
| Properdin | 1 | 1976 | 8 | 0.040 |
Why?
| HLA-DR Antigens | 5 | 1991 | 228 | 0.040 |
Why?
| Interferon-gamma | 2 | 1991 | 747 | 0.040 |
Why?
| Infant, Extremely Low Birth Weight | 1 | 2016 | 15 | 0.040 |
Why?
| Cattle | 5 | 1991 | 994 | 0.040 |
Why?
| Rats, Inbred Strains | 5 | 1987 | 392 | 0.040 |
Why?
| ROC Curve | 1 | 2018 | 494 | 0.040 |
Why?
| Plasma Cells | 2 | 1987 | 60 | 0.040 |
Why?
| Drug Resistance, Microbial | 1 | 1996 | 71 | 0.030 |
Why?
| Proteins | 2 | 2020 | 953 | 0.030 |
Why?
| Chronic Disease | 4 | 1990 | 1645 | 0.030 |
Why?
| Magnesium | 2 | 1986 | 156 | 0.030 |
Why?
| Syndrome | 2 | 1987 | 363 | 0.030 |
Why?
| Neoplasm Metastasis | 1 | 2017 | 563 | 0.030 |
Why?
| HIV Infections | 1 | 2009 | 2532 | 0.030 |
Why?
| Multivariate Analysis | 1 | 2019 | 1531 | 0.030 |
Why?
| Dose-Response Relationship, Drug | 4 | 1988 | 1981 | 0.030 |
Why?
| Intensive Care Units, Neonatal | 1 | 2017 | 184 | 0.030 |
Why?
| Proteomics | 1 | 2020 | 890 | 0.030 |
Why?
| Glycoproteins | 1 | 1976 | 323 | 0.030 |
Why?
| Conjunctival Neoplasms | 2 | 1984 | 6 | 0.030 |
Why?
| Retinal Hemorrhage | 2 | 1986 | 20 | 0.030 |
Why?
| Blood Proteins | 2 | 1989 | 249 | 0.030 |
Why?
| Recurrence | 2 | 1988 | 998 | 0.030 |
Why?
| Diagnosis, Differential | 2 | 1988 | 1423 | 0.030 |
Why?
| Hypoglycemic Agents | 1 | 2021 | 1055 | 0.030 |
Why?
| Granulomatous Disease, Chronic | 2 | 1983 | 62 | 0.030 |
Why?
| Antibodies, Antinuclear | 2 | 1992 | 59 | 0.030 |
Why?
| Fluorescent Antibody Technique | 4 | 1989 | 420 | 0.030 |
Why?
| Immunity, Cellular | 2 | 1985 | 276 | 0.030 |
Why?
| T-Lymphocytes, Regulatory | 7 | 1994 | 367 | 0.030 |
Why?
| Models, Biological | 2 | 2016 | 1756 | 0.030 |
Why?
| Immunization | 2 | 1985 | 421 | 0.030 |
Why?
| Dinoprostone | 2 | 1990 | 193 | 0.030 |
Why?
| Eye Infections | 1 | 1992 | 2 | 0.030 |
Why?
| Models, Statistical | 1 | 2016 | 651 | 0.030 |
Why?
| Cells, Cultured | 5 | 1991 | 4162 | 0.030 |
Why?
| Cell Line | 5 | 1991 | 2785 | 0.030 |
Why?
| Antigens, Differentiation, T-Lymphocyte | 2 | 1989 | 87 | 0.030 |
Why?
| Propionibacterium acnes | 1 | 1991 | 11 | 0.030 |
Why?
| Sepsis | 2 | 1984 | 546 | 0.030 |
Why?
| Epitopes | 3 | 1990 | 450 | 0.030 |
Why?
| Indomethacin | 2 | 1990 | 76 | 0.030 |
Why?
| Kinetics | 2 | 1988 | 1658 | 0.030 |
Why?
| Biological Transport, Active | 1 | 1991 | 74 | 0.020 |
Why?
| Dogs | 2 | 1990 | 382 | 0.020 |
Why?
| Transforming Growth Factor beta | 2 | 1991 | 468 | 0.020 |
Why?
| Immunoglobulin lambda-Chains | 1 | 1990 | 6 | 0.020 |
Why?
| Severity of Illness Index | 1 | 2019 | 2784 | 0.020 |
Why?
| Coronary Circulation | 1 | 1991 | 121 | 0.020 |
Why?
| Microcirculation | 1 | 1991 | 162 | 0.020 |
Why?
| Random Allocation | 2 | 1988 | 360 | 0.020 |
Why?
| B-Lymphocytes | 2 | 1987 | 936 | 0.020 |
Why?
| Endothelium, Corneal | 1 | 1990 | 12 | 0.020 |
Why?
| Cefazolin | 1 | 1990 | 20 | 0.020 |
Why?
| Protein Binding | 2 | 1989 | 2010 | 0.020 |
Why?
| Fluorescein | 1 | 1989 | 28 | 0.020 |
Why?
| Flow Cytometry | 2 | 1992 | 1128 | 0.020 |
Why?
| Keratitis | 2 | 1994 | 14 | 0.020 |
Why?
| Recombinant Proteins | 2 | 1991 | 1318 | 0.020 |
Why?
| Kidney Function Tests | 2 | 1989 | 166 | 0.020 |
Why?
| Osmolar Concentration | 1 | 1989 | 185 | 0.020 |
Why?
| Diagnostic Errors | 1 | 1990 | 171 | 0.020 |
Why?
| Retroviridae Proteins | 1 | 1989 | 12 | 0.020 |
Why?
| Hemocyanins | 2 | 1988 | 58 | 0.020 |
Why?
| Antimetabolites | 1 | 1989 | 27 | 0.020 |
Why?
| Alkylating Agents | 1 | 1989 | 27 | 0.020 |
Why?
| Heptanoates | 1 | 1988 | 2 | 0.020 |
Why?
| Pneumonia, Pneumocystis | 1 | 1989 | 32 | 0.020 |
Why?
| Drug Eruptions | 1 | 1989 | 28 | 0.020 |
Why?
| Interferon Type I | 1 | 1990 | 134 | 0.020 |
Why?
| Suramin | 1 | 1988 | 6 | 0.020 |
Why?
| Toxoplasmosis | 1 | 1989 | 31 | 0.020 |
Why?
| Candidiasis | 1 | 1989 | 59 | 0.020 |
Why?
| Receptors, Virus | 1 | 1989 | 78 | 0.020 |
Why?
| HIV Envelope Protein gp120 | 1 | 1989 | 64 | 0.020 |
Why?
| Heptanoic Acids | 1 | 1988 | 64 | 0.020 |
Why?
| Reverse Transcriptase Inhibitors | 1 | 1989 | 85 | 0.020 |
Why?
| Corneal Injuries | 1 | 1989 | 37 | 0.020 |
Why?
| Lung Diseases | 2 | 1986 | 764 | 0.020 |
Why?
| Dexamethasone | 2 | 1987 | 323 | 0.020 |
Why?
| Placebos | 1 | 1988 | 204 | 0.020 |
Why?
| Mycobacterium Infections | 1 | 1989 | 65 | 0.020 |
Why?
| Antigen-Antibody Complex | 2 | 1985 | 92 | 0.020 |
Why?
| Injections | 1 | 1989 | 171 | 0.020 |
Why?
| Lens, Crystalline | 1 | 1990 | 126 | 0.020 |
Why?
| Central Nervous System Diseases | 1 | 1989 | 64 | 0.020 |
Why?
| Sugar Alcohol Dehydrogenases | 1 | 1987 | 6 | 0.020 |
Why?
| Elapid Venoms | 1 | 1987 | 15 | 0.020 |
Why?
| HIV Seropositivity | 1 | 1989 | 117 | 0.020 |
Why?
| Galactosemias | 1 | 1987 | 8 | 0.020 |
Why?
| Imidazolidines | 1 | 1987 | 19 | 0.020 |
Why?
| Colchicine | 1 | 1987 | 27 | 0.020 |
Why?
| Blood-Retinal Barrier | 1 | 1987 | 14 | 0.020 |
Why?
| Specific Gravity | 1 | 1987 | 13 | 0.020 |
Why?
| Receptors, Interleukin-2 | 1 | 1987 | 73 | 0.020 |
Why?
| Antigens, Differentiation | 1 | 1987 | 82 | 0.020 |
Why?
| Prednisone | 2 | 1986 | 234 | 0.020 |
Why?
| Community Health Services | 1 | 2009 | 216 | 0.020 |
Why?
| Retinol-Binding Proteins, Plasma | 1 | 1987 | 5 | 0.020 |
Why?
| Drug Interactions | 1 | 1989 | 356 | 0.020 |
Why?
| Onchocerciasis | 1 | 1987 | 7 | 0.020 |
Why?
| Herpesviridae Infections | 1 | 1989 | 144 | 0.020 |
Why?
| Pituitary-Adrenal System | 1 | 1989 | 179 | 0.020 |
Why?
| Papilledema | 1 | 1987 | 36 | 0.020 |
Why?
| Down-Regulation | 1 | 1990 | 654 | 0.020 |
Why?
| Aldehyde Reductase | 1 | 1987 | 101 | 0.020 |
Why?
| Leukocytes, Mononuclear | 1 | 1990 | 514 | 0.020 |
Why?
| Molecular Weight | 1 | 1987 | 346 | 0.020 |
Why?
| Organ Specificity | 1 | 1987 | 287 | 0.020 |
Why?
| Sclera | 1 | 1987 | 36 | 0.020 |
Why?
| Macaca mulatta | 1 | 1987 | 145 | 0.020 |
Why?
| Heart Rate | 1 | 1991 | 756 | 0.020 |
Why?
| Hypothalamo-Hypophyseal System | 1 | 1989 | 215 | 0.020 |
Why?
| Dihydroergotoxine | 1 | 1986 | 2 | 0.020 |
Why?
| Indium | 1 | 1986 | 9 | 0.020 |
Why?
| Receptors, Immunologic | 1 | 1987 | 228 | 0.020 |
Why?
| Lipopolysaccharides | 1 | 1990 | 875 | 0.020 |
Why?
| Peritoneal Cavity | 1 | 1986 | 25 | 0.020 |
Why?
| Wound Healing | 1 | 1989 | 279 | 0.020 |
Why?
| Mutation | 1 | 2017 | 3493 | 0.020 |
Why?
| Imidazoles | 1 | 1987 | 234 | 0.020 |
Why?
| Radioisotopes | 1 | 1986 | 36 | 0.020 |
Why?
| Muramidase | 1 | 1986 | 73 | 0.020 |
Why?
| Immune Tolerance | 1 | 1988 | 355 | 0.020 |
Why?
| Serum Albumin | 1 | 1986 | 151 | 0.020 |
Why?
| Reference Values | 4 | 1989 | 789 | 0.020 |
Why?
| Osteoporosis | 1 | 1989 | 234 | 0.020 |
Why?
| Double-Blind Method | 3 | 2001 | 1711 | 0.020 |
Why?
| Prognosis | 2 | 1985 | 3563 | 0.020 |
Why?
| Peptide Fragments | 1 | 1990 | 715 | 0.020 |
Why?
| Connective Tissue | 1 | 1985 | 38 | 0.020 |
Why?
| Pigmentation Disorders | 1 | 1985 | 7 | 0.020 |
Why?
| Acute Disease | 2 | 1987 | 984 | 0.020 |
Why?
| Tetanus Toxoid | 1 | 1985 | 38 | 0.020 |
Why?
| Rabbits | 1 | 1986 | 808 | 0.020 |
Why?
| Vascular Diseases | 1 | 1988 | 251 | 0.020 |
Why?
| Retinitis Pigmentosa | 1 | 1984 | 17 | 0.020 |
Why?
| Lymphadenitis | 1 | 1984 | 4 | 0.020 |
Why?
| Pemphigoid, Benign Mucous Membrane | 1 | 1984 | 3 | 0.020 |
Why?
| Salmonella typhimurium | 1 | 1986 | 179 | 0.020 |
Why?
| Blood Sedimentation | 1 | 1984 | 34 | 0.020 |
Why?
| Potassium | 1 | 1985 | 150 | 0.020 |
Why?
| Fibrosis | 1 | 1987 | 497 | 0.020 |
Why?
| Tissue Distribution | 1 | 1985 | 339 | 0.020 |
Why?
| Kidney Glomerulus | 1 | 1985 | 133 | 0.020 |
Why?
| Longitudinal Studies | 1 | 1992 | 2599 | 0.020 |
Why?
| Chlorides | 1 | 1985 | 142 | 0.020 |
Why?
| Antibodies | 1 | 1987 | 400 | 0.020 |
Why?
| Referral and Consultation | 1 | 2009 | 669 | 0.020 |
Why?
| Isotretinoin | 1 | 1984 | 23 | 0.020 |
Why?
| Oculomotor Muscles | 1 | 1984 | 40 | 0.020 |
Why?
| Kidney Tubules, Proximal | 1 | 1985 | 131 | 0.020 |
Why?
| Peptides | 1 | 1990 | 893 | 0.020 |
Why?
| Acne Vulgaris | 1 | 1984 | 28 | 0.020 |
Why?
| Uveal Diseases | 1 | 1983 | 5 | 0.020 |
Why?
| Complement C3 | 1 | 1985 | 192 | 0.020 |
Why?
| Optic Neuritis | 1 | 1984 | 37 | 0.020 |
Why?
| Chediak-Higashi Syndrome | 1 | 1983 | 7 | 0.010 |
Why?
| Carbon Dioxide | 1 | 1985 | 237 | 0.010 |
Why?
| Rats, Inbred BN | 2 | 1994 | 51 | 0.010 |
Why?
| Anemia | 1 | 1984 | 156 | 0.010 |
Why?
| Kidney Failure, Chronic | 1 | 1989 | 519 | 0.010 |
Why?
| Chemical and Drug Induced Liver Injury | 1 | 1984 | 141 | 0.010 |
Why?
| Liver Diseases | 1 | 1986 | 325 | 0.010 |
Why?
| Combined Modality Therapy | 1 | 1986 | 1174 | 0.010 |
Why?
| Fluorometry | 1 | 1981 | 21 | 0.010 |
Why?
| Immunochemistry | 3 | 1986 | 13 | 0.010 |
Why?
| Liver | 1 | 1990 | 1827 | 0.010 |
Why?
| Melanosis | 1 | 1981 | 17 | 0.010 |
Why?
| Eyelid Diseases | 1 | 1981 | 14 | 0.010 |
Why?
| Computers | 1 | 1981 | 66 | 0.010 |
Why?
| Histocytochemistry | 3 | 1986 | 84 | 0.010 |
Why?
| Uric Acid | 1 | 1984 | 354 | 0.010 |
Why?
| Edema | 1 | 1982 | 130 | 0.010 |
Why?
| Immunoglobulin G | 1 | 1985 | 804 | 0.010 |
Why?
| Confidence Intervals | 1 | 2001 | 339 | 0.010 |
Why?
| Calcium | 1 | 1986 | 1244 | 0.010 |
Why?
| T-Lymphocytes, Cytotoxic | 2 | 1994 | 160 | 0.010 |
Why?
| HLA-DQ Antigens | 2 | 1991 | 178 | 0.010 |
Why?
| Protease Inhibitors | 1 | 1999 | 106 | 0.010 |
Why?
| Arthus Reaction | 2 | 1987 | 9 | 0.010 |
Why?
| Permeability | 2 | 1987 | 155 | 0.010 |
Why?
| Sucrose | 2 | 1987 | 105 | 0.010 |
Why?
| Photoreceptor Cells | 2 | 1987 | 13 | 0.010 |
Why?
| Macrophages | 2 | 1994 | 1334 | 0.010 |
Why?
| Immunologic Techniques | 2 | 1986 | 41 | 0.010 |
Why?
| Survival Analysis | 1 | 1999 | 1325 | 0.010 |
Why?
| Tissue Donors | 2 | 1989 | 337 | 0.010 |
Why?
| Transplantation, Isogeneic | 1 | 1994 | 17 | 0.010 |
Why?
| Blotting, Southern | 1 | 1994 | 68 | 0.010 |
Why?
| DNA, Protozoan | 1 | 1994 | 28 | 0.010 |
Why?
| Shock, Septic | 1 | 1976 | 213 | 0.010 |
Why?
| Eye Enucleation | 1 | 1993 | 10 | 0.010 |
Why?
| Didanosine | 1 | 1993 | 14 | 0.010 |
Why?
| Viral Proteins | 2 | 1985 | 300 | 0.010 |
Why?
| Zidovudine | 1 | 1993 | 78 | 0.010 |
Why?
| Drug Tolerance | 1 | 1993 | 77 | 0.010 |
Why?
| Mice | 2 | 1986 | 15888 | 0.010 |
Why?
| Disease Progression | 1 | 1999 | 2546 | 0.010 |
Why?
| Cell Cycle | 1 | 1994 | 584 | 0.010 |
Why?
| Neutrophils | 2 | 1987 | 1246 | 0.010 |
Why?
| Cyclophosphamide | 1 | 1991 | 223 | 0.010 |
Why?
| HLA-DP Antigens | 1 | 1991 | 33 | 0.010 |
Why?
| Thromboxane A2 | 1 | 1990 | 13 | 0.010 |
Why?
| Histocompatibility Testing | 1 | 1990 | 123 | 0.010 |
Why?
| Immunophenotyping | 1 | 1991 | 288 | 0.010 |
Why?
| Leukotriene B4 | 1 | 1990 | 56 | 0.010 |
Why?
| Antigen-Presenting Cells | 1 | 1990 | 157 | 0.010 |
Why?
| Biological Assay | 1 | 1991 | 123 | 0.010 |
Why?
| Radioimmunoassay | 1 | 1990 | 168 | 0.010 |
Why?
| Aspartate Aminotransferases | 1 | 1990 | 96 | 0.010 |
Why?
| Alanine Transaminase | 1 | 1990 | 152 | 0.010 |
Why?
| Alkaline Phosphatase | 1 | 1990 | 161 | 0.010 |
Why?
| T-Lymphocyte Subsets | 1 | 1992 | 409 | 0.010 |
Why?
| Epoprostenol | 1 | 1990 | 141 | 0.010 |
Why?
| Immunoglobulins | 1 | 1990 | 166 | 0.010 |
Why?
| Lupus Erythematosus, Systemic | 1 | 1992 | 235 | 0.010 |
Why?
| Coroners and Medical Examiners | 1 | 1989 | 8 | 0.010 |
Why?
| Virus Cultivation | 1 | 1989 | 25 | 0.010 |
Why?
| Adrenal Cortex | 1 | 1988 | 36 | 0.010 |
Why?
| Methods | 1 | 1988 | 67 | 0.010 |
Why?
| Chemical Fractionation | 1 | 1988 | 29 | 0.010 |
Why?
| Arterioles | 1 | 1988 | 49 | 0.010 |
Why?
| Survival Rate | 1 | 1993 | 1810 | 0.010 |
Why?
| Glial Fibrillary Acidic Protein | 1 | 1988 | 86 | 0.010 |
Why?
| Metaraminol | 1 | 1987 | 1 | 0.000 |
Why?
| Rats, Inbred WKY | 1 | 1987 | 39 | 0.000 |
Why?
| Rats, Inbred SHR | 1 | 1987 | 41 | 0.000 |
Why?
| Peroxidases | 1 | 1987 | 26 | 0.000 |
Why?
| Mannitol | 1 | 1987 | 34 | 0.000 |
Why?
| Adrenal Gland Neoplasms | 1 | 1988 | 82 | 0.000 |
Why?
| Cell Membrane Permeability | 1 | 1987 | 89 | 0.000 |
Why?
| Edetic Acid | 1 | 1987 | 48 | 0.000 |
Why?
| Propionibacterium | 1 | 1986 | 2 | 0.000 |
Why?
| Leukocyte Count | 1 | 1988 | 309 | 0.000 |
Why?
| HIV Antigens | 1 | 1987 | 17 | 0.000 |
Why?
| AIDS-Related Complex | 1 | 1986 | 4 | 0.000 |
Why?
| Mitosis | 1 | 1988 | 175 | 0.000 |
Why?
| Serum Albumin, Bovine | 1 | 1987 | 69 | 0.000 |
Why?
| Blood-Brain Barrier | 1 | 1987 | 107 | 0.000 |
Why?
| Carcinoma | 1 | 1988 | 212 | 0.000 |
Why?
| Cytotoxicity Tests, Immunologic | 1 | 1986 | 49 | 0.000 |
Why?
| Argon | 1 | 1986 | 20 | 0.000 |
Why?
| Homosexuality | 1 | 1986 | 17 | 0.000 |
Why?
| Agranulocytosis | 1 | 1986 | 32 | 0.000 |
Why?
| Cell Division | 1 | 1988 | 788 | 0.000 |
Why?
| Antigens, Viral | 1 | 1987 | 181 | 0.000 |
Why?
| RNA-Directed DNA Polymerase | 1 | 1985 | 34 | 0.000 |
Why?
| Regional Blood Flow | 1 | 1987 | 427 | 0.000 |
Why?
| Light | 1 | 1988 | 346 | 0.000 |
Why?
| Hydrogen Peroxide | 1 | 1987 | 299 | 0.000 |
Why?
| Tissue and Organ Procurement | 1 | 1989 | 243 | 0.000 |
Why?
| Interleukin-1 | 1 | 1990 | 987 | 0.000 |
Why?
| Amino Acid Sequence | 1 | 1990 | 2123 | 0.000 |
Why?
| Biomarkers, Tumor | 1 | 1992 | 1076 | 0.000 |
Why?
| Drug Synergism | 1 | 1986 | 346 | 0.000 |
Why?
| Pilot Projects | 1 | 1990 | 1477 | 0.000 |
Why?
| Brain Neoplasms | 1 | 1993 | 1016 | 0.000 |
Why?
| Drug Evaluation, Preclinical | 1 | 1986 | 187 | 0.000 |
Why?
| HLA-B27 Antigen | 1 | 1985 | 12 | 0.000 |
Why?
| Anterior Eye Segment | 1 | 1985 | 10 | 0.000 |
Why?
| Autoantigens | 1 | 1988 | 407 | 0.000 |
Why?
| Hyperemia | 1 | 1985 | 43 | 0.000 |
Why?
| Indians, North American | 1 | 1990 | 597 | 0.000 |
Why?
| Molecular Sequence Data | 1 | 1990 | 2933 | 0.000 |
Why?
| DNA | 1 | 1992 | 1401 | 0.000 |
Why?
| Epithelial Cells | 1 | 1991 | 995 | 0.000 |
Why?
| Lymphokines | 1 | 1984 | 132 | 0.000 |
Why?
| Structure-Activity Relationship | 1 | 1986 | 536 | 0.000 |
Why?
| Gram-Negative Bacteria | 1 | 1985 | 72 | 0.000 |
Why?
| Hodgkin Disease | 1 | 1986 | 121 | 0.000 |
Why?
| Ischemia | 1 | 1987 | 382 | 0.000 |
Why?
| Monocytes | 1 | 1987 | 523 | 0.000 |
Why?
| Cryptococcosis | 1 | 1984 | 23 | 0.000 |
Why?
| Prevalence | 1 | 1990 | 2442 | 0.000 |
Why?
| Lymphatic Diseases | 1 | 1983 | 18 | 0.000 |
Why?
| Clone Cells | 1 | 1984 | 255 | 0.000 |
Why?
| alpha 1-Antitrypsin | 1 | 1985 | 123 | 0.000 |
Why?
| Colitis | 1 | 1986 | 227 | 0.000 |
Why?
| Antibodies, Viral | 1 | 1986 | 551 | 0.000 |
Why?
| Meningitis | 1 | 1984 | 74 | 0.000 |
Why?
| Pain | 1 | 1988 | 746 | 0.000 |
Why?
| Microscopy, Fluorescence | 1 | 1984 | 418 | 0.000 |
Why?
| Kidney Transplantation | 1 | 1988 | 584 | 0.000 |
Why?
| Biomechanical Phenomena | 1 | 1985 | 705 | 0.000 |
Why?
| Vasodilation | 1 | 1985 | 462 | 0.000 |
Why?
| Mice, Inbred BALB C | 1 | 1984 | 1245 | 0.000 |
Why?
| Endothelium, Vascular | 1 | 1988 | 923 | 0.000 |
Why?
| Clinical Trials as Topic | 1 | 1986 | 985 | 0.000 |
Why?
| Blood Pressure | 1 | 1987 | 1713 | 0.000 |
Why?
| Killer Cells, Natural | 1 | 1983 | 386 | 0.000 |
Why?
| Pneumonia, Viral | 1 | 1986 | 361 | 0.000 |
Why?
| Sexual Behavior | 1 | 1984 | 470 | 0.000 |
Why?
| Mycobacterium Infections, Nontuberculous | 1 | 1984 | 334 | 0.000 |
Why?
| Lung | 1 | 1985 | 3830 | 0.000 |
Why?
|
|
Palestine's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|